Dendritic cell-based xenoantigen vaccination for prostate cancer Immunotherapy

Journal of Immunology

Volumn 167, Issue 12, 2001, Pages 7150-7156

  Fong, L ^a   Brockstedt, D ^a   Benike, C ^a   Breen, J K ^a   Strang, G ^a   Ruegg, C L ^a   Engleman, E G ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ANTIGEN; HETEROANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; IMMUNIZATION; IMMUNOGENICITY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; T LYMPHOCYTE; TH1 CELL; VACCINATION;

EID: 0035892759     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.12.7150     Document Type: Article

References (43)

1. Cancer statistics, 2000
2. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides
3. Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man
4. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer
5. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocytemacrophage colony-stimulating factor using ex vivo gene transfer
6. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer
7. Nonprostatic sources of prostate-specific antigen
8. Prostate-specific membrane antigen expression in normal and malignant human tissues
9. Prostate-specific membrane antigen expression in the duodenum: Implications in coeliac disease and immunotherapy for prostate cancer
10. Characterization of anti-prostatic acid phosphatase monoclonal antibody and its medical significance
11. Improved immunohistochemical detection of prostatic acid phosphatase by a monoclonal antibody
12. Gene expression and prostate specificity of human prostatic acid phosphatase (PAP): Evaluation by RNA blot analyses
13. Molecular cloning and sequence analysis of cDNA encoding human prostatic acid phosphatase
14. Primary structure of rat secretory acid phosphatase and comparison to other acid phosphatases
15. Selection of the T cell repertoire
16. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: Implications for immunotherapy of prostate cancer
17. gp100/pmel 17 is a murine tumor rejection antigen: Induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand
18. Tumor immunity and autoimmunity induced by immunization with homologous DNA
19. Dendritic cells in cancer immunotherapy
20. + CTLs from naive precursors
21. + T cell lines from naive precursors
22. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
23. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
24. Prospects for adoptive T cell therapy
25. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
26. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
27. Bolus injection of aqueous antigen leads to a high density of T-cell-receptor ligand in the spleen, transient T-cell activation and anergy induction
28. Induction of T cell anergy by high concentrations of immunodominant native peptide is accompanied by IL-10 production and a block in JNK activity
29. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells
30. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of NF-KB activation in hemopoietic progenitor cells
31. + progenitors by tumor cells: Role of interleukin-6 and macrophage colony-stimulating factor
32. The immune system in the elderly. II. Specific cellular immunity
33. Dendritic cells injected via different routes induce immunity in cancer patients
34. The third function of the thymus
35. + T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35)
36. Heteroclitic immunization induces tumor immunity
37. Dominant determinants in hen eggwhite lysozyme correspond to the cryptic determinants within its self-homologue, mouse lysozyme: Implications in shaping of the T cell repertoire and autoimmunity
38. The self-directed T cell repertoire against mouse lysozyme reflects the influence of the hierarchy of its own determinants and can be engaged by a foreign lysozyme
39. Observations on the doubling time of prostate cancer: The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume
40. Peptide and carbohydrate vaccines in relapsed prostate cancer: Immunogenicity of synthetic vaccines in man: Clinical trials at Memorial Sloan-Kettering Cancer Center
41. + T cells in the antitumor immune response
42. + T cell responses in antitumor immunity
43. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines